Shares of Moderna Inc (NASDAQ:MRNA) are trading higher Tuesday morning. Sentiment has shifted sharply toward Moderna’s oncology pipeline following Phase 3 clinical data for its personalized cancer vaccine program, supporting the stock’s 150% surge over the trailing month.
Here’s what investors need to know.
- Moderna stock is charging ahead with explosive momentum. What’s driving MRNA stock higher?
Phase 3 Cancer Vaccine Breakthrough Drives Re-Rating
The primary catalyst driving Moderna’s stock higher is late-August Phase 3 trial data for intismeran autogene (mRNA-4157), its individualized cancer therapy developed with Merck.
The trial met its primary endpoints, demonstrating that mRNA-4157 combined with Keytruda significantly reduced the risk of recurrence and distant metastasis in high-risk melanoma patients post-resection.
The successful Phase 3 readout serves as validation for Moderna’s therapeutic mRNA platform beyond respiratory viruses, opening up multi-billion-dollar addressable oncology markets and shifting investor focus to upcoming regulatory submissions.
Closing Of $2.6 Billion Convertible Notes Offering
Moderna is scheduled to formally close its upsized $2.6 billion offering of convertible senior notes on Tuesday. The capital raise strengthens Moderna’s cash position as it funds the commercial launch of its updated vaccines, advances late-stage mRNA pipeline candidates, including its personalized cancer vaccine partnership with Merck, and maintains aggressive R&D investments without near-term balance sheet friction.
Upcoming Investor Conference Presentations
Moderna on Tuesday confirmed its schedule for two upcoming September healthcare conferences. Company executives will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 10 a.m. ET, followed by the Bernstein Insights third Annual Healthcare Forum on Wednesday, Sept. 23, at 8:50 a.m. ET. Both presentations will be broadcast live via webcast on the company’s investor relations portal.
MRNA Shares Climb Tuesday Morning
MRNA Price Action: Moderna shares were up 3.06% at $144.63 at the time of publication on Tuesday, according to Benzinga Pro data.
Image: Shutterstock
